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Background: Fast implementation of positron emission tomography (PET) into clinical
and preclinical studies highly demands automated synthesis for the preparation of PET
radiopharmaceuticals in a safe and reproducible manner. The aim of this study was to
develop automated synthesis methods for these six 18F-labeled radiopharmaceuticals
produced on a routine basis at the University of Pennsylvania using the AllinOne
synthesis module.
Results: The development of automated syntheses with varying complexity was
accomplished including HPLC purification, SPE procedures and final formulation with
sterile filtration. The six radiopharmaceuticals were obtained in high yield and high
specific activity with full automation on the AllinOne synthesis module under current
good manufacturing practice (cGMP) guidelines.
Conclusion: The study demonstrates the versatility of this synthesis module for the
preparation of a wide variety of 18F-labeled radiopharmaceuticals for PET imaging studies.
Keywords: PET, Radiotracer, Automation, AllinOne, HPLC, SPE, ISO-1, FTP, FTT, F-GlnBackground
Positron emission tomography (PET) facilities have recently been growing exponen-
tially as PET is an especially sensitive molecular imaging technique quantitatively
measuring tracers in nano- to picomolar range in comparison with other modalities
like magnetic resonance imaging (MRI) or computerized tomography (CT). The main
limitation of PET is the short half-lives of the radionuclides used in the development
of PET radiotracers. Among the most popular positron-emitting radionuclides, short
half-life radionuclides like oxygen-15 and nitrogen-13 are used for brain perfusion
studies ([15O]H2O) and heart perfusion studies ([
13N]NH3) respectively (Bergmann
et al., 1989; Grüner et al., 2011; Muzik et al., 1993). The 20.4 min half-life of carbon-11
and the rapid production of reactive intermediates such as [11C]methyl iodide and
[11C]methyltriflate have facilitated the generation of 11C-labeled radiotracers for a var-
iety of imaging applications. However, the 110 min half-life of fluorine-18 has firmly
established itself as the radionuclide of choice for imaging applications since it allows
for longer data acquisition for dynamic imaging studies and high count rates for me-
tabolite analyses which are often required for quantitative PET imaging studies. In2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
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emitted positron has a short mean range (2.39 mm in water) (Vallabhajosula, 2009).
The methods for fluorine-18 labeling have been greatly improved in the last 30 years,
largely due to recent advances in organic fluorination chemistry (Brooks et al., 2014;
Jacobson et al., 2015; Kamlet et al., 2013; Li and Conti, 2010; Mach and Schwarz, 2010;
Rotstein et al., 2014). Therefore, the utilization of 18F-labeled radiopharmaceuticals for hu-
man studies has expanded greatly in various areas of clinical research, such as cancer,
neurological disorders, and cardiac diseases. The key requirements for the synthesis of ra-
diopharmaceuticals used for clinical PET studies are reproducibility, reliability and short
synthesis time. Full automation is also important, especially for general-purpose nucleo-
philic radiofluorination reactions. The historical background and evolution of automated
synthesis for radiopharmaceuticals has been described in a number of excellent reviews (I
Sachinidis et al., 2010; Krasikova, 2007; Preshlock et al., 2016; Shao et al., 2011; Welch and
Redvanly, 2003), and a guidance on current good radiopharmaceuticals using automated
modules was created in Europe in 2014 (Aerts et al., 2014). There are a number of
commercially-available automated synthesis modules designed for [18F]FDG radiosynthesis,
and these have been modified for the synthesis of other 18F-labeled radiotracers. These auto-
mated modules are designed to conduct 2–3 organic reactions, followed by either resin-
based SPE and/or HPLC purification. Examples of commercial modules include FAS-
TLabTM, TracerLab™ FXFN series (GE Healthcare), E-Z modules (Eckert & Ziegler modular
lab) and Explora® series (Siemens Healthcare). Recently, the AllinOne, an automated
synthesizer by Trasis, was developed as a universal GMP-compliant synthesis module for
radiolabeling of radiotracers with short half-life radionuclides. This module is described as
being versatile and capable of handling complex chemistry. The instrument can be broken
down to the chemistry module, purification module and reformulation module. Disposable
cassettes, reagents and components are used to ease the burden on cleaning. Successful pro-
duction with high yield and high specific activity to the following compound, such as
[18F]F-DOPA, [18F]FDG, [18F]MPPF, [18F]FES, [18F]F-MISO, [18F]FET, and [18F]FLT has
been reported (Otabashi et al., 2015). These radiotracers were developed many years ago
and have been used on either an intermediate to widespread basis in PET imaging studies.
Although [18F]FDG is an effective tumor-imaging agent for diagnosis, staging, restaging
and monitoring various malignant conditions, its utilization has several well-known limi-
tations (Lind et al., 2004; Liu et al., 2014; Lubezky et al., 2007; Pery et al., 2010; Suzuki
et al., 2008), such as non FDG-avid tumors (e.g. prostate cancer) and non-cancerous
FDG-avid tissue (e.g. inflammatory tissue). Therefore, the introduction of new PET radio-
pharmaceuticals capable of filling these gaps is clearly needed. Recently, glutamine was
suggested as alternative source of metabolic energy for tumor cells (Wise et al., 2008).
Glutaminolysis, especially in myc-overexpressing cells, plays a significant role in tumor
growth and metabolism. Fluorine-substituted glutamine analogs have been particularly
useful in PET imaging studies, with [18F]-(2S,4R)4-Fluoroglutamine ([18F]F-Gln) being the
most promising metabolic tracer for imaging glutamine metabolism (Lieberman et al.,
2011; Ploessl et al., 2012; Qu et al., 2010).
The development of small molecules targeting proteins overexpressed in cancer
cells is another application that is gaining and has increased importance in onco-
logic imaging studies. For example, the sigma-2 receptor is overexpressed in most
human and murine tumors and has been proposed as a biomarker for imaging
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tracer [18F]ISO-1 was evaluated in Balb/c female mice bearing EMT-6 mammary al-
lografts, and an initial evaluation of this radiotracer in patients with either
lymphoma, breast or head & neck cancer was recently reported (Tu et al., 2007).
The high correlation of tumor-to-muscle ratio to Ki-67 scores indicates that
[18F]ISO-1 may provide a novel method for imaging the proliferative status of solid
tumors. [18F]ISO-1 may be capable of stratifying patients into groups of high or low
proliferative status, which is expected to be useful in selecting patients who are
likely to respond to cell cycle specific chemotherapeutics (Dehdashti et al., 2013).
Meanwhile, poly ADP-ribose polymerase-1 (PARP-1) is critical to DNA repair and
PARP-1 inhibition has been demonstrated as an effective method for inducing syn-
thetic lethality in cancers depending on PARP-1 activity for survival. The uptake of
the PARP-1 radiotracer, [18F]FluorThanatrace ([18F]FTT), was found to correlate
with PARP-1 expression (Edmonds et al., 2016; Zhou et al., 2014). Quantifying tu-
moral PARP-1 activity with PET should be particularly useful for occupancy studies
aimed at determining the optimal dose of a PARP-1 inhibitor generating an optimal
therapeutic response.
In addition to radiopharmaceuticals used for cancer imaging, a number of receptor-
based radiopharmaceuticals have been developed to study a wide variety of central ner-
vous system (CNS) disorders including Alzheimer’s disease (AD), Parkinson’s disease
(PD), depression and drug addiction (Sokoloff et al., 1990). [18F]Flubatine, short for (-)-
[18F]flubatine, has been used to image nicotinic acetylcholine receptors (nAChRs) since
a dysfunction of the cholinergic neurotransmitter system is one factor contributing to
cognitive decline in neurodegenerative disorders such as Alzheimer’s disease (Bois
et al., 2015; Gallezot et al., 2014; Hockley et al., 2013; Wu et al., 2010). [18F]Fallypride
has been developed to study extrastriatal dopamine D2 receptor expression in a number
of neuropsychiatric disorders (Mukherjee et al., 1995; Mukherjee et al., 1997; Mukher-
jee et al., 2002; Riccardi et al., 2006; Slifstein et al., 2010). And finally, our group has de-
veloped the first high affinity, D3–selective PET ligand, [
18F]Fluortriopride ([18F]FTP),
which has demonstrated feasibility for imaging D3 receptors in non-human primate
brain, following depletion of endogenous dopamine (Mach et al., 2011; Tu et al., 2011).
Although straightforward in theory, the adaptation of structurally-diverse PET radio-
tracer syntheses onto an automated system requires considerable expertise in the field of
organic chemistry and chemical engineering. In the current report, we describe the fully
automated syntheses on the AllinOne module of the six radiotracers described above
(Fig. 1). The automation process includes radiolabeling, purification, formulation and sys-
tem cleaning. To date, [18F]ISO-1, [18F]FTP and [18F]FTT have been reliably produced for
use in phase 0 clinical studies, while [18F]F-Gln, [18F]flubatine and [18F]fallypride were
used for microPET, cell uptake and metabolism studies.
Methods
Materials for synthesis and analysis
[18F]F-Gln tosylate precursor, (2S, 4R)-tert-butyl-2-(tert-butoxycarbonylamino)-5-oxo-4-
(tosyloxy)-5-(2, 4, 6-trimethoxybenzylamino)pentanoate, and reference standard were ob-
tained from MSKCCC (New York, USA) or from Dr. Hank Kung. [18F]ISO-1 reference
standard and its mesylate precursor, 2-(2-((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-
Fig. 1 Structures of six radiotracers synthesized on the AllinOne module
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and its precursor, 2-(4-(6-oxo-6,7,8,9-tetrahydro-2,7,9a-triazabenzo[cd]azulen-1-yl)phenox-
y)ethyl 4-methylbenzenesulfonate; and [18F]FTP reference standard and its precursor 2-(2-
(4-(4-(4-(thiophen-2-yl)benzamido)butyl)piperazin-1-yl)phenoxy)ethyl methanesulfonate,
were made in our lab under GLP conditions. Cryptand (as shown as K222 in the following
text), [18F]fallypride reference standard and its tosylate precursor, and [18F]flubatine refer-
ence standard and its iodide precursor were all obtained from ABX (Radeberg, German).
Acetonitrile (MeCN, anhydrous for synthesis; HPLC grade for purification and analysis),
dimethylformamide (DMF, anhydrous, dried over molecular sieves (4 Å)), dimethyl sulfox-
ide (DMSO, anhydrous, dried over molecular sieves (4 Å)), methanol (MeOH, HPLC
grade), potassium carbonate (K2CO3, ACS grade), ammonium formate (NH4HCO2, ACS
grade), ammonium bicarbonate (NH4HCO3, ACS grade) were purchased from Sigma-
Aldrich (St Louis, USA). Water (DIUF grade) and trifluoroacetic acid (TFA, anhydrous,
HPLC grade) were purchased from Fisher Scientific (Pittsburgh, USA). Cartridges used for
solid phase extractions, such as Sep-Pak QMA Carb Cartridges, Sep-Pak C18 Plus Car-
tridges, Sep-Pak tC18 Cartridges, Alumina N Plus Cartridges, Sep-Pak Dry Sodium Sulfate
Plus Long Cartridges, and Sep-Pak Silica Plus Long Cartridges, were purchased from Wa-
ters (Milford, USA). Sterile water for injection (250 mL bags) was purchased from B. Braun
(Melsungen, Germany). Sterile normal saline (0.9 % w/v) was purchased from Hospira (Lake
Forest, USA) and ethanol (200 proof, USP grade) was from Decon Labs (King of Prussia,
USA). 18O water (>97 %) was purchased from Huayi Isotopes (Changshu, China) or ABX
(Radeberg, Germany). Low-protein binding 0.2 μm sterile filters, Millex® FG filters, were ob-
tained from Millipore (Bedford, USA) and 0.45 μm nylon filters, Whatman Puradisc®, were
purchased from GE Healthcare (Marlborough, USA). All other chemicals and solvents for
radiosyntheses were obtained from Sigma-Aldrich or Fisher Scientific. These chemicals are
at least ACS grade and used without further purification. AllinOne synthesis module and all
consumable parts were purchased from TRASIS (Ans, Belgium).
Instrumentation for general procedures
The AllinOne synthesis module is a thirty-actuator version (with option for 18–36 ac-
tuators), with two reaction vessels, and a built-in HPLC system with UV detector and
radioactivity detector. The cassette is structured around zero dead volume three-way
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moved freely. Each position can be assigned to reagent vials, SPE cartridges, syringes or
others functions. Those connections are mostly through spikes and tubing. All compo-
nents are compatible with the most aggressive acids, bases and solvents. Generally
speaking, we use the first six valves for F-18 drying, the second set of valves for first-
step of radiolabeling and the third set for second-step reaction and/or sample prepar-
ation prior to HPLC purification. Product formulation is generally accomplished by the
last set of valves. Figure 2 displays the module with loaded cassette and reagents for
[18F]F-Gln. Synthesis protocols are generated using the accompanying user-friendly
software that allows the user to string together all sequences for each operational step,
such as drying, radiolabeling and formulating, to one synthesis method. Figure 3 shows
the user interface for [18F]ISO-1 and Fig. 4 shows the user interface for [18F]F-Gln.
After synthesis, the reaction module is left for decay until the next day due to the con-
cern of radiation exposure. It is, however, possible to develop a cleaning protocol to
rinse off the residual radioactivity from the cassette and vials if the need for using the
module a second time arises.
Preconditioning is necessary for some cartridges before synthesis. Silica Plus Car-
tridges and Dry Sodium Sulfate Plus Long Cartridges were used as received. QMA Carb
Cartridges were treated with 10 mL 0.2 M K2CO3 solution followed by 20 mL of water.
C18 Plus and tC18 Cartridges were preconditioned with 1 mL ethanol, and followed by
rinse with 10 mL water. Alumina-N Plus Cartridges were treated with 10 mL water. All
conditioned cartridges were kept wet unless otherwise specified. Typically, it takes
thirty minutes to one hour to set up the module before receiving radioactivity to start
the radiosynthesis. After loading the appropriate labeling program, the “machine check”
sequence is performed to ensure module readiness including nitrogen pressure, com-
pressed air pressure, vacuum, heating, cooling, and movement of syringe and manifold
actuators. After kit installation, a “kit check” sequence is initiated to assure that the kit
has been properly installed. After reagents are loaded, the module is ready to receive
radioactivity for radiosynthesis.Fig. 2 AllinOne synthesis module with mounted disposable kits and reagents for [18F]FGln
Fig. 3 AllinOne user software interface for one-vessel reaction ([18F]ISO-1)
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La-Neuve, Belgium), via the 18O (p, n) 18F reaction. The initial radiolabeling was performed
manually with a small amount radioactivity, 30–50 mCi, in a lead-shielded hot cell. When a
desirable radiolabeling condition was found, the procedures were programmed into the Alli-
nOne with the standard pressure and vacuum condition for drying [18F]F- and radiolabeling
temperature and duration adapted from the manual radiolabling. The program would beFig. 4 AllinOne user software interface for two-vessel reaction ([18F]F-Gln)
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out fluoride source. Afterward, a small amount of starting radioactivity, 30–50 mCi, would
be used to test whether the parameters from manual labeling can be translated directly to
automated syntheses. Adjustment on the [18F]F- drying and the radiolabeling temperature
and duration are the two most common parameters that require optimization before the
radiolabeling processes are set.
The radiolabeling was performed in a 6 mL flat-bottom glass vial with silicone crimp-
cap with 2 tubing inlets. Therefore, for all the radiotracers that we adapted to the Alli-
nOne module, the volume of radiolabeling solvent has to be adjusted to be at least
0.6 mL. To concentrate the collected radiotracer fraction after semi-preparative HPLC
purification, C18 Sep-Pak cartridges were also incorporated into the automation process.
Some adjustment on the semi-prep HPLC condition was also needed to provide better
separation. These are the extent of optimization for [18F]fallypride and [18F]flubatine as
we currently only use these two radiotracers for pre-clinical studies. Additional
optimization details are described in Radiolabeling methods for [18F]F-Gln, [18F]ISO-1,
[18F]FTP, and [18F]FTT. The final reaction conditions are listed in Fig. 5. Generally speak-
ing, the precursor was heated in an aprotic solvent (DMSO, DMF or MeCN) with the cor-
responding phase-transfer reagent (K222 or 18-crown-6) for a predetermined time,
followed by deprotection step when required, and then quenched with the HPLC mobile
phase for purification.
Purification of all [18F]-labeled PET tracers included semi-preparative HPLC purifica-
tion and solid phase extraction. Unreacted [18F]F- was removed from the reaction mixture
via Alumina N Plus cartridge prior to loading to HPLC. HPLC purification was performed
with the built-in semi-preparative HPLC system equipped with a radioactivity detector,
Smartline UV detector 200 (Knauer, Berlin, Germany) and a HPLC pump P4.1.5 (Knauer,
Berlin, Germany). For semi-preparative HPLC purification columns, Luna® C18 column,
5 μm, 100 Å, 250 × 10 mm, was purchased from Phenomenex® (Torrance, USA); ZOR-
BAX StableBond SB-C18 column, 5 μm 80 Å, 100 × 9.4 mm, was purchased from Agilent
(Santa Clara, USA); SunFire C18 semi-preparative column, 5 μm, 250 × 10 mm, was pur-
chased from Waters (Milford, USA).
Analytical HPLC was performed with a Waters Alliance e2695 HPLC system (Milford,
USA) equipped with 2489 UV/VIS detector and photomultiplier scintillation radio-
detector (Eckert&Ziegler, Berlin Germany). Zorbax XDB-C18, 5 μm 80 Å 150 × 4.6 mm,
column (Agilent, Santa Clara, USA) was used for chemical and radiochemical purity test-
ing for [18F]ISO-1, [18F]FTP, [18F]FTT, [18F]flubatine and [18F]fallypride. Phenomenex
Chirex® 3126 (D)-penicillin column, 5 μm 250 × 4.6 mm (Santa Clara, USA)) and Sigma-
Aldrich Astec® CHIROBIOTIC™ T Chiral column, 5 μm 250 × 4.6 mm (St Louis, USA)
were used to confirm the enantiomeric of [18F]F-Gln. Residual solvent analysis was per-
formed using an Agilent gas chromatography (GC) system, 6890 or 7890 series. All GCs
and HPLCs were controlled with Waters Empower software.Radiolabeling methods
The labeling methods are listed in Table 1. Most of the processes utilize a one-step re-
action, involving only one reaction vessel and a solid phase cartridge enrichment after
HPLC purification. Although the synthesis of [18F]flubatine is a two-step reaction, the
Fig. 5 Scheme for the radiosyntheses of the six radiotracers












[18F]ISO-1 50 40 ± 5 1000–14,000 60 One vessel, one step,
HPLC, SPE
[18F]FTT 40 52 ± 3 1000–35,304 55 One vessel, one step,
HPLC, SPE
[18F]FTP 12 11 ± 2 2500–4680 60 One vessel, one step,
HPLC, SPE
[18F]Fallypride 3 68 ± 2 2380–3200 45 One vessel, one step,
HPLC, SPE
[18F]Flubatine 2 30 ± 1 3119–3220 60 One vessel, two steps,
HPLC, SPE
[18F]F-Gln 25 11 ± 3 >40b 98 Two vessels, two steps,
HPLC, SPE
aRun time was defined from start of synthesis (radioactivity measured on QMA after radioactivity delivery) to end of
synthesis (product formulated in final product vial), including drying [18F]F-, reaction, purification and formulation
Starting activity ranged from 30 mCi to 1500 mCi; with 30–50 mCi for the developmental runs and 500–1500 mCi for
clinical productions
bBased on the limit of quantitation from UV spectra
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exception. That is, the process is complicated, consisting of a two-step, two reaction-
vessel followed by a multiple purification procedure including HPLC purification of the
intermediate radiolabeled compound.Synthesis of [18F]ISO-1
The one-pot synthesis of [18F]ISO-1 was performed in AllinOne module for animal and
clinical studies. [18F]F- in O-18 water was delivered from cyclotron to the module and
trapped by passing the solution through a preconditioned QMA Carb cartridge. Release
of [18F]F- from QMA Carb cartridge to the reaction vessel was achieved by eluting with
a 1 mL basic eluent (0.85 mL MeCN and 0.15 mL water containing 7 mg K222 and
2 mg K2CO3). Subsequent drying of the solution was conducted at 100 °C for 2 min
under vacuum. Anhydrous MeCN (1 mL) was then added to the reaction vessel for
azeotropic removal of residual water.
The literature reported method used microwave as the means for radiolabeling. The
Trasis module has two conventional heating chambers. Therefore, the radiolabeling method
has to been changed to thermo heating. This change also resulted in consistent radiolabel-
ing yields. The mesylate precursor (1.5 mg) in 0.8 mL DMSO was added into the reaction
vessel containing dried [18F]F-, K2CO3 and K222. The reaction mixture was heated at
100 °C for 10 min and then quenched with 3 mL mobile phase. The reaction mixture was
passed through an Al-N Plus cartridge before transfer to HPLC loop. The cartridge was
washed with an additional 3 mL of water. Unreacted [18F]F- was trapped on an Al-N Plus
cartridge and the crude mixture was purified by a semi-preparative HPLC with an Agilent
SB-C18 column (5 μm, 100 × 9.4 mm). The mobile phase was 39 % MeOH in 0.1 M
NH4HCO2 buffer at a flow rate of 5 mL/min. The desired product was eluted at approxi-
mately 25 min and the fraction (~10 mL) was collected in a 20 mL syringe and then di-
luted with water. The mixture was passed through a C18 Plus cartridge and rinsed with
10 mL water. The product was eluted with 1.5 mL ethanol and passed through a 0.2 μm
sterile Millex® FG filter into final product vial. The final formulation was prepared by add-
ing 15 mL saline into the final product vial.Synthesis of [18F]FTT
[18F]FTT was synthesized on the AllinOne using a similar procedure as described for
[18F]ISO-1. The precursor that was initially reported was the mesylate precursor. It was
found that this precursor gave about 5 % decay-corrected yield. To increase the radiolabel-
ing yield, tosylate precursor was synthesized and radiolabeled. The average yield for tosylate
precursor is around 50 % and was then used for the later studies.
The precursor solution (0.8 mg in 0.8 ml DMF) was added to the dried [18F]F-/K222 in
the reaction vessel and the solution was heated at 105 °C for 10 min. After cooling to ambi-
ent temperature and removing unreacted [18F]F- with an Al-N Plus cartridge, the reaction
mixture was purified by a semi-preparative HPLC using an Agilent SB-C18 column (5 μm,
100 × 9.4 mm) and eluting with a mobile phase of 17 % MeCN in 20 mM NH4HCO3 solu-
tion at 5 ml/min flow rate. The purified product was reformulated in the final product vial
with saline containing ≤ 10 % ethanol.
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[18F]FTP was synthesized on the AllinOne using a similar procedure as [18F]ISO-1.
After drying of [18F]F-, a aliquot of DMSO was added to dry [18F]F-/K222/K2CO3 com-
plex prior to the addition of [18F]FTP precursor during the manual radiolabeling. The
same process cannot be achieved with an automated module. Therefore, another radi-
olabeling solvent, MeCN, was tested and gave satisfactory radiolabeling results. The
mesylate precursor (1.5 mg) was dissolved in 0.8 mL of MeCN. The radiolabeling was
carried out at 100 °C for 10 min. The semi-preparative HPLC purification was con-
ducted on Phenomenex Kinetex® 5 μm 150 × 10 mm column and mobile phase of 40 %
MeCN in 20 mM NH4HCO3 with flow rate of 5 mL/min. The collected product was
trapped on a tC18 Sep-Pak cartridge and the final product was formulated with ≤ 10 %
ethanol in saline.Synthesis of [18F]fallypride
The synthesis of [18F]fallypride was adapted from literature with adjustment on the vol-
ume of radiolabeling solvent (Mukherjee et al., 2002). The overall process is similar to
the process used for [18F]ISO-1. The tosylated precursor (4 mg) in 1 mL MeCN was
added to the dried [18F]F-complex and heated at 100 °C for 10 min for radiolabeling.
After cooling to room temperature, the reaction mixture was quenched with mobile
phase and passed through an Al-N Plus cartridge to remove unreacted [18F]F- prior to
injection onto a semi-preparative HPLC for purification. Phenomenex Luna C18 (2)
column (5 μm, 250 × 10 mm) with mobile phase of 60 % MeCN/40 % 0.1 N NaHCO3
in water with a flow rate of 5 mL/min was used. The collected product was enriched
and rinsed in tC18 Sep-Pak cartridge and the final product was formulated with ≤10 %
ethanol in saline.Synthesis of [18F]flubatine
The one-vessel, two-step synthesis of [18F]flubatine was achieved by displacing the qua-
ternary ammonium leaving group on the precursor with [18F]F- and then hydrolyzing
N-Boc group. The only optimization of this radiotracer to an automated process was to
adjust the volume of radiolabeling solvent. The solution of flubatine precursor (1 mg)
in DMSO (0.6 mL) was added to the dried [18F]F- complex and heated at 100 °C for
10 min. The reaction mixture was cooled to 80 °C, 1 N HCl solution (1 mL) was the
mixture heated at that temperature for 4 min to complete the deprotection step. After
cooling to 50 °C, the reaction mixture was neutralized with 1 N NaOH solution (1 mL)
and purified via semi-preparative HPLC with a Waters Sunfire column (5 μm, 250 ×
10 mm) and mobile phase of 4 % ethanol in PBS buffer at 5 mL/min flow rate was
used. The collected product was ready for use after sterile filtration.Synthesis of [18F]F-Gln
The synthesis of [18F]F-Gln, following the route published by Qu et al. (Qu et al.,
2010), was developed on the Trasis AllinOne module as a two-vessel, two-step auto-
mated procedure. The first step was radiolabeling the precursor and the second step in-
volved removal of the three protecting groups. We employed the published
radiolabeling process but devoted some effort to find the optimal drying condition for
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is essential to a successful radiolabeling as this is a moisture-sensitive reaction.
After eluting [18F]F- from the QMA cartridge, a mild phase-transfer reagent (18-
crown-6/KHCO3) was added and the [
18F]F- was dried at 90 °C for 10 min. Precursor
(~10 mg) in 1 mL of MeCN was added into the first reaction vessel and the radiolabel-
ing was carried out at 85 °C for 20 min. The intermediate was purified by a semi-prep
HPLC system equipped with a Phenomenex Luna C18 column and mobile phase of
55 % MeCN in water at a flow rate of 5 mL/min. The intermediate was collected and
passed through a pre-conditioned C18 cartridge to concentrate the radioactivity, which
was then eluted with ether and passed through a dry cartridge to the second reaction
vessel for the deprotection step. One mL of TFA and 10 μL of anisole were added to
the reaction vessel followed by heating at 70 °C for 5 min. The TFA and anisole were
removed under nitrogen flow and vacuum. The crude product was dissolved in ether
and the mixture was trapped by passing through a Silica Plus cartridge. The final prod-
uct, [18F]F-Gln, was eluted with saline into the final product vial.Quality control results
Limited quality control (QC) testing, including testing for pH, radiochemical and
chemical purity and identity by HPLC, and residual solvent testing by GC, were per-
formed on [18F]fallypride, [18F]flubatine, and [18F]F-GLN for preclinical studies. Other
radiotracers, such as [18F]ISO-1, [18F]FTT, [18F]FTP, had to pass a more rigorous set of
QC specifications prior to release for clinical research studies. We followed relevant
regulatory guidances, such as USP Chapter 823 and the FDA 21 CFR Part 212. The
tests included filter integrity test via bubble test, appearance via visual test, pH test via
pH paper, radionuclide identity and purity test via half-life and energy spectrum, radio-
chemical purity and identity test via analytical HPLC, chemical purity via HPLC, re-
sidual solvent analysis via GC, K222 spot test, pyrogenicity, and sterility. An example of
QC specifications is listed in Table 2.Results and Discussion
Six 18F-labeled radiopharmaceuticals were produced with full automation on the Trasis
AllinOne module without any hardware modification. The processes gave good yields,
product purities and specific activities of the final products. The summary of labeling
method, decay-corrected radiochemical yield, specific activity at EOS and run time of
all six compounds is listed in Table 1.
The Trasis AllinOne module is an easy-to-use and versatile module with user-
friendly software and interface. Complicated labeling methods requiring two reaction
vessels and multiple Sep-Pak purifications can be conducted on it, such as [18F]FDopa
and [18F]F-Gln. There are multiple built-in radioactivity detectors in the AllinOne mod-
ule so one can track the trending of radioactivity over time. Radioactivity trending for
[18F]ISO-1 synthesis is shown in Fig. 6 and the radioactivity trending for [18F]F-Gln
synthesis is shown in Fig. 7. With simultaneous trending, it is easy to check the results
of parameter optimization during method development as well as identifying errors
when deviations occur during the synthesis. Other trend tracks, such as pressure,
temperature, and flow rate are also useful for method development.
Fig. 6 Radioactivity trending of [18F]ISO-1
Table 2 Specifications of ISO-1 for clinical studies
Test Acceptance criteria
Filter membrane integrity test Following manufacturer’s specification
pH 4.5–7.5
Appearance Clear, colorless, and particle-free
Strength (@EOS) 4–14 mCi/mL
Radionuclide identity (dose calibrator) 105.0 min to 115.0 min
Radionuclidic purity (annual test) ≥99.5 % of phantoms
Radiochemical purity ≥90 %
Radiochemical identity RT difference of radioactivity and reference peaks≤ 10 %
Drug mass ≤10 μg/ injection dose
Chemical impurity ≤10 μg/ injection dose
Kryptofix ≤50 μg/mL
Bacterial Endotoxin ≤175 EU/ total dose
Residue solvent: MeCN ≤0.41 mg/mL
(4.1 mg/day max)
Residue solvent: MeOH ≤3 mg/mL
(30 mg/day max)
Residue solvent: EtOH ≤100 mg/mL
Residue solvent: DMSO ≤5 mg/mL
(50 mg/day max)
Sterility (results after 14 days) Sterile (no visible growth)
Li et al. EJNMMI Radiopharmacy and Chemistry  (2016) 1:15 Page 12 of 19
Fig. 7 Radioactivity trending of [18F]F-Gln
Li et al. EJNMMI Radiopharmacy and Chemistry  (2016) 1:15 Page 13 of 19For this module, the UV detector operates at a fixed wavelength of 254 nm.
Hence, the HPLC is good for production but not preferable for method develop-
ment. A tunable UV detector would improve the application range of the module.
In addition, replacing the flat-bottom reaction vessel with a conical or V-shape re-
action vessel would make it possible to reduce the solvent volume and improve the
module performance.Fig. 8 A view of typical semi-preparative chromatogram of [18F]fubatine
Fig. 9 A view of typical semi-preparative chromatogram of [18F]fallypride
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collection. The collected HPLC fraction can only be diluted with water into a
20 mL syringe before loading the sample on a C18 cartridge. Therefore, methods
for semi-preparative HPLC must be well developed to make sure the trapping on
the cartridge is sufficient. The semi-preparative HPLC method of [18F]flubatine has
been optimized from literature, with the chromatogram shown in Fig. 8; semi-prepFig. 10 A view of typical semi-preparative chromatogram of [18F]FTT
Fig. 11 A view of typical semi-preparative chromatogram of [18F]FTP
Li et al. EJNMMI Radiopharmacy and Chemistry  (2016) 1:15 Page 15 of 19HPLC methods for [18F]ISO-1, [18F]FTT, [18F]FTP, and [18F]fallypride have also
been developed to incorporate solid phase purification and give good mass purity,
as the semi-prep chromatograms showed in Figs. 9, 10, 11 and 12. Figure 13 shows
a typical semi-preparative HPLC chromatography of the purification of [18F]ISO-1.
The typical radiochemical purities for all radiotracers are greater than 97 %, exceptFig. 12 A view of typical semi-preparative chromatogram of [18F]F-Gln
Fig. 13 A view of typical semi-preparative chromatogram of [18F]ISO-1
Li et al. EJNMMI Radiopharmacy and Chemistry  (2016) 1:15 Page 16 of 19for [18F]F-Gln (purity ≥ 90 %). A typical [18F]ISO-1 analytical HPLC chromatogram
is shown in Fig. 14, demonstrating the high radiochemical and chemical purities.
In addition to semi-prep HPLC method development for the module, Sep-Pak purifi-
cation has been also done for radiotracer production. The synthesis and purification of
[18F]F-Gln is more complicated than the other radiotracers described in this study, re-
quiring more than the typical semi-preparative purification and Sep-Pak isolation/elu-
tion. Two additional solid phase purifications were introduced in the process. After the
initial radiolabeling step and prior to deprotection, the intermediate was isolated and
eluted by ether and passage through a Dry Sodium Sulfate Plus Long cartridge toFig. 14 A view of typical analytical chromatogram of [18F]ISO-1
Fig. 15 Analytical Radio-HPLC chromatography of [18F]F-Gln with different chiral columns
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easily removed by evaporation. In contrast to the literature method in which the direct
formulation was done in the second reaction vessel, further purification of the final
[18F]F-Gln product was enhanced by introducing a silica cartridge to purify the reaction
mixture after deprotection. The final product was trapped on a Silica cartridge to allow
for the removal of anisole, TFA and other chemical impurities. The product was eluted
with ether and the ether residue was then removed by nitrogen flow under vacuum.
The final product was formulated with normal saline or phosphate buffered saline.
Typical [18F]F-Gln analytical HPLC chromatograms with two different conditions are
shown in Fig. 15. It was found that the method with Astec CHIROBIOTIC™ T Chiral
HPLC column can be used for both radiochemical purity and enantiomer purity. It pro-
vides both radiochemical purity and enantiomeric purity with shorter run time than the
literature method (Qu et al., 2010). Furthermore, this method works well for metabol-
ism studies for [18F]F-Gln.Conclusion
We have conducted the fully automated synthesis of six 18F-labeled PET tracers on the
AllinOne synthesis module without hardware reconfiguration. All tracers were pro-
duced in radiochemical yield and with a run time compatible with that required for
routine production for PET imaging studies. Three radiotracers are currently being
used in clinical research studies using the methods described in this report.Abbreviations
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